Video
Examining financial factors in prostate cancer treatment patterns
Author(s):
“I think the key [is to not] get rid of financial incentives. I don't think that's possible. [Rather, we should] align financial incentives [so] that [we] can promote what is best for patients,” says Lillian Y. Lai, MD.
Video Player is loading.
In this video, Lillian Y. Lai, MD, discusses the findings of the Urology Practice study, “Commercial prices for prostatectomy and treatment among younger, privately insured men with prostate cancer.” Lai is a Society of Urologic Oncology fellow at the University of Michigan, Ann Arbor.
Related Videos
John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Endourologist discusses shared decision-making and laser lithotripsy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Related Content
